GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CASI Pharmaceuticals Inc (FRA:ENM) » Definitions » Valuation Rank

CASI Pharmaceuticals (FRA:ENM) Valuation Rank


View and export this data going back to 2007. Start your Free Trial

What is CASI Pharmaceuticals Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

CASI Pharmaceuticals Valuation Rank Related Terms

Thank you for viewing the detailed overview of CASI Pharmaceuticals's Valuation Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

CASI Pharmaceuticals (FRA:ENM) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CASI Pharmaceuticals Inc (FRA:ENM) » Definitions » Valuation Rank
Comparable Companies
ABIO LEXX EQ OCUP KRON ALGS AADI CLNN MLEC INAB OCSE:NOVO B VRTX REGN ASX:CSL MRNA XKRX:207940 XKRX:068270 XBRU:UCB BNTX XBRU:ARGX
Traded in Other Exchanges
CASI:USA
Address
9620 Medical Center Drive, Suite 300, Rockville, MD, USA, 20850
Website
https://www.casipharmaceuticals.com
CASI Pharmaceuticals Inc is a biopharmaceutical company that focuses on commercializing innovative therapeutics and pharmaceutical products. The products include injections for patients who are suffering from leukemias and lymphomas. The EVOMELA injection is used as a conditioning treatment before autologous stem cell transplant for patients with multiple myeloma. The company products include CID-103, CNCT19, EVOMELA, MARQIBO, ZEVALIN, ENMD-2076 and others. The majority of the revenue is generated from the product sales of EVOMELA. The company primarily operates in the United States, Canada, China and other parts of the world.